JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

Search

Simulations Plus Inc

Închisă

SectorSănătate

15.31 -8.81

Rezumat

Modificarea prețului

24h

Curent

Minim

15.12

Maxim

16.67

Indicatori cheie

By Trading Economics

Venit

1.4M

676K

Vânzări

961K

18M

P/E

Medie Sector

48.528

84.243

EPS

-0.034

Randament dividend

0.48

Marjă de profit

3.67

Angajați

212

EBITDA

-3M

2.3M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+13.3% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.48%

2.28%

Următoarele câștiguri

2 apr. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-30M

338M

Deschiderea anterioară

24.12

Închiderea anterioară

15.31

Sentimentul știrilor

By Acuity

34%

66%

95 / 352 Clasament în Healthcare

Simulations Plus Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 feb. 2026, 23:11 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb. 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 feb. 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb. 2026, 23:38 UTC

Câștiguri

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb. 2026, 23:29 UTC

Achiziții, Fuziuni, Preluări

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb. 2026, 23:27 UTC

Achiziții, Fuziuni, Preluări

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb. 2026, 23:25 UTC

Achiziții, Fuziuni, Preluări

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb. 2026, 23:23 UTC

Achiziții, Fuziuni, Preluări

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb. 2026, 23:22 UTC

Achiziții, Fuziuni, Preluări

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb. 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb. 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3 feb. 2026, 22:56 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb. 2026, 22:40 UTC

Câștiguri

Amdocs Extends Collaboration With T-Mobile

3 feb. 2026, 22:39 UTC

Câștiguri

Amdocs 1Q Adj EPS $1.81

3 feb. 2026, 22:39 UTC

Câștiguri

Amdocs 1Q Rev $1.16B

3 feb. 2026, 22:39 UTC

Câștiguri

Amdocs 1Q EPS $1.45 >

3 feb. 2026, 22:38 UTC

Câștiguri

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb. 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb. 2026, 22:14 UTC

Câștiguri

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb. 2026, 22:13 UTC

Câștiguri

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb. 2026, 22:12 UTC

Câștiguri

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb. 2026, 22:10 UTC

Câștiguri

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb. 2026, 22:10 UTC

Câștiguri

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb. 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb. 2026, 22:10 UTC

Câștiguri

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb. 2026, 22:09 UTC

Câștiguri

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb. 2026, 22:09 UTC

Câștiguri

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Comparație

Modificare preț

Simulations Plus Inc Așteptări

Obiectiv de preț

By TipRanks

13.3% sus

Prognoză pe 12 luni

Medie 19 USD  13.3%

Maxim 19 USD

Minim 19 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSimulations Plus Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

4 ratings

2

Cumpărare

2

Păstrare

0

Vânzare

Sentiment

By Acuity

95 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat